Ostrich CEOs: Only 24 percent of Pharma CEOs said that rising expectations will affect how they do business.
"What came out of this survey is that the life sciences industry is one that's in the middle of a big transition, but what's interesting is that CEOs are saying that the journey has just begun," said Michael E. Svinte, vice president of global pharmaceutical and life sciences at IBM. "They are so bombarded with change that they are struggling to keep up with it."
One odd fact of note is that while 62 percent of life science CEOs said they view rising expectations of corporate responsibility as a positive trend, only 24 percent of respondents said that those rising expectations will affect how they do business.
In the study, IBM questions whether this is because they already have programs in place to be more responsible with the environment and helping fight disease in impoverished nations, or whether they just don't have the strategies in place.